Repros Holds Meeting With FDA, Says It Is Clear FDA No Closed To Entering Secondary Hypogonadism As An Indication
February 08, 2016 at 16:02 PM EST
Repros Therapeutics Inc.® (Nasdaq: RPRX) today announced that on February 4, 2016, the Company attended a productive meeting with FDA ...
